Polycystic Ovary Syndrome: Raising awareness and changing the name led by experts, health professionals and those with lived experience
Peer-Reviewed Publication
Updates every hour. Last Updated: 13-Nov-2025 01:11 ET (13-Nov-2025 06:11 GMT/UTC)
Most experts and those experiencing the potentially debilitating features of Polycystic Ovary Syndrome (PCOS), which affects one in eight women, want greater awareness and a name change to improve care and outcomes. A new Monash University-led research paper reveals those involved are keen to overcome the misleading implication that it is only an ovarian or gynaecological condition.
A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.
Insilico Medicine recently unveiled a groundbreaking study developing small molecule inhibitors targeting ENPP1 to effectively modulate the STING pathway and enhance tumor immunity. Published in Nature Communications, the study showcases Insilico's advanced generative AI platform and integrated workflow which identified and validated ENPP1 as a critical immune checkpoint among multiple solid tumors and assisted in developing a highly specific oral ENPP1 inhibitor, ISM5939.